Linagliptin

Type 2 diabetes

Bullous pemphigoid

Endocrinology

Dermatology

Pemphigoid

Environmental health

Immunology

Vildagliptin

Physics

Optics

Political science

Population

Internal medicine

MEDLINE

Medicine

Scopus

Incidence (geometry)

Antibody

Diabetes mellitus

Journal of Investigative Dermatology

Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease (Schmidt and Zillikens, 2013). BP has become more common over the past two decades (Försti et al., 2014; Joly et al., 2012; Langan et al., 2008). However, the underlying causes of the increasing incidence of BP are poorly understood. Altogether, over 50 drugs have been reported to induce BP (Stavropoulos et al., 2014). The use of dipeptidyl peptidase-4 inhibitors (DPP-4i), a class of drug used for the treatment of diabetes, has recently been scrutinized as a risk factor for BP, both in case reports (see Supplementary Table S1 online) and in national pharmacovigilance database reports (Bene et al., 2016; García et al., 2016), but large population-based studies are lacking.

Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study